At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Adenovirus/PSA Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy
In Brief
A Phase 2 clinical trial evaluating Adenovirus/PSA Vaccine for Recurrent Prostate Cancer. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether vaccination with the Ad/PSA vaccine will induce an anti-PSA immunity that will result in the destruction of the remaining prostate cancer cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Prostate Cancer
CountriesUnited States
CollaboratorsUnited States Department of Defense
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedDec 2007
Primary CompletionDec 2020
Study CompletionJan 2023
TodayJul 2026
First PostedDec 31, 2007
Enrollment StartDec 1, 2007
Primary CompletionDec 31, 2020
Study CompletionJan 31, 2023
TodayJul 2, 2026
Enrollment to primary: 13.1 yearsPosted 18.5 years ago
Interventions
Adenovirus/PSA Vaccinebiological
1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60